This article is a correction to:
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
Haoning Guo
Bin Wang
Shuying Yuan1- 1Division of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China
- 2Clinical Experimental Center, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China
- 3Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China
by Guo H, Wang B, Yuan S, Wu S, Liu J, He M and Wang J (2022). Front. Pharmacol. 13:849758. doi: 10.3389/fphar.2022.849758
In the original article, there was an error in affiliation 1. Instead of “Division of Psychopharmacology, Department of Pharmacy, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Division of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”. In the published article, there was an error in affiliation 3. Instead of “Department of Pathology, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: esketamine, pharmacovigilance, neurological adverse events, signal, FAERS, disproportionality analysis
Citation: Guo H, Wang B, Yuan S, Wu S, Liu J, He M and Wang J (2022) Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system. Front. Pharmacol. 13:1075966. doi: 10.3389/fphar.2022.1075966
Received: 21 October 2022; Accepted: 24 October 2022;
Published: 09 November 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Guo, Wang, Yuan, Wu, Liu, He and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jing Liu, ljing_syy@163.com; Miaoquan He, hmiaoquan_syy@163.com; Jisheng Wang, wjisheng_syy@163.com